Janney Montgomery Scott restated their buy rating on shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) in a research note published on Friday, July 21st. Janney Montgomery Scott currently has a $15.00 target price on the specialty pharmaceutical company’s stock.
A number of other brokerages have also recently commented on AGRX. HC Wainwright assumed coverage on shares of Agile Therapeutics in a research note on Wednesday, July 19th. They set a buy rating and a $10.00 price target on the stock. Royal Bank Of Canada set a $8.00 price target on shares of Agile Therapeutics and gave the company a buy rating in a research note on Sunday, July 16th. ValuEngine upgraded shares of Agile Therapeutics from a strong sell rating to a sell rating in a research note on Saturday, July 8th. Noble Financial restated a buy rating on shares of Agile Therapeutics in a research note on Wednesday, June 14th. Finally, Cantor Fitzgerald restated a buy rating and set a $9.00 price target on shares of Agile Therapeutics in a research note on Monday, May 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $9.93.
Shares of Agile Therapeutics (NASDAQ:AGRX) traded down 2.95% during mid-day trading on Friday, hitting $4.60. The company had a trading volume of 113,230 shares. The firm has a 50-day moving average of $4.12 and a 200-day moving average of $3.19. The company’s market cap is $132.51 million. Agile Therapeutics has a 12 month low of $1.82 and a 12 month high of $8.15.
Agile Therapeutics (NASDAQ:AGRX) last released its earnings results on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.02. During the same quarter in the previous year, the firm earned ($0.29) earnings per share. On average, analysts expect that Agile Therapeutics will post ($1.07) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://stocknewstimes.com/2017/08/01/janney-montgomery-scott-reaffirms-buy-rating-for-agile-therapeutics-inc-agrx-updated.html.
In other news, Chairman Alfred Altomari bought 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 11th. The shares were acquired at an average price of $3.51 per share, with a total value of $35,100.00. Following the acquisition, the chairman now owns 151,587 shares of the company’s stock, valued at approximately $532,070.37. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Renee Selman bought 53,333 shares of the firm’s stock in a transaction that occurred on Thursday, May 11th. The shares were purchased at an average cost of $3.68 per share, for a total transaction of $196,265.44. Following the acquisition, the insider now directly owns 53,333 shares in the company, valued at approximately $196,265.44. The disclosure for this purchase can be found here. Corporate insiders own 3.50% of the company’s stock.
Several institutional investors have recently modified their holdings of AGRX. Royce & Associates LP raised its position in shares of Agile Therapeutics by 206.1% in the first quarter. Royce & Associates LP now owns 987,582 shares of the specialty pharmaceutical company’s stock worth $3,165,000 after buying an additional 665,000 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Agile Therapeutics by 209.2% in the fourth quarter. Renaissance Technologies LLC now owns 64,000 shares of the specialty pharmaceutical company’s stock worth $365,000 after buying an additional 43,300 shares during the last quarter. Finally, Janney Montgomery Scott LLC bought a new position in shares of Agile Therapeutics during the second quarter worth approximately $122,000. 79.77% of the stock is currently owned by hedge funds and other institutional investors.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
